# Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

> **NCT04971746** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 58 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** GLPG4716
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT04971746
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-19
- **Primary completion:** 2022-05-09
- **Final completion:** 2022-05-09
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971746, "Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04971746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*